GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Asset Turnover

BRAIN Biotech AG (XTER:BNN) Asset Turnover : 0.21 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BRAIN Biotech AG's Revenue for the three months ended in Mar. 2024 was €14.47 Mil. BRAIN Biotech AG's Total Assets for the quarter that ended in Mar. 2024 was €69.86 Mil. Therefore, BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2024 was 0.21.

Asset Turnover is linked to ROE % through Du Pont Formula. BRAIN Biotech AG's annualized ROE % for the quarter that ended in Mar. 2024 was -40.76%. It is also linked to ROA % through Du Pont Formula. BRAIN Biotech AG's annualized ROA % for the quarter that ended in Mar. 2024 was -10.98%.


BRAIN Biotech AG Asset Turnover Historical Data

The historical data trend for BRAIN Biotech AG's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Asset Turnover Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only 0.55 0.55 0.51 0.64 0.74

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.18 0.21 0.19 0.21

Competitive Comparison of BRAIN Biotech AG's Asset Turnover

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Asset Turnover Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Asset Turnover falls into.



BRAIN Biotech AG Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BRAIN Biotech AG's Asset Turnover for the fiscal year that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=55.335/( (77.992+70.937)/ 2 )
=55.335/74.4645
=0.74

BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=14.474/( (66.471+73.249)/ 2 )
=14.474/69.86
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BRAIN Biotech AG  (XTER:BNN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BRAIN Biotech AG's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-7.672/18.8225
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.672 / 57.896)*(57.896 / 69.86)*(69.86/ 18.8225)
=Net Margin %*Asset Turnover*Equity Multiplier
=-13.25 %*0.8287*3.7115
=ROA %*Equity Multiplier
=-10.98 %*3.7115
=-40.76 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BRAIN Biotech AG's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-7.672/69.86
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-7.672 / 57.896)*(57.896 / 69.86)
=Net Margin %*Asset Turnover
=-13.25 %*0.8287
=-10.98 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BRAIN Biotech AG Asset Turnover Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines